Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples